Since significant antitumor cell cytotoxicity was observed with combination treatment of 225Ac‐lintuzumab and venetoclax in AML cell lines, we evaluated this combination therapy in AML subcutaneous transplantation models using OCI‐AML3 and U937 xenografts in SCID mice. This evidence concerns the gene RUNX2 and acute myeloid leukemia.